X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Arakoda (tafenoquine) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
Arakoda (tafenoquine) is the inhibitor of hematin polymerization which is being evaluated in phase 2 clinical trials for the treatment of babesiosis patients.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Arakoda (tafenoquine) is an oral hematin polymerization inhibitor, small mlecule drug which is being evaluated in preclinical studies for the treatment of hospitalized babesiosis.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 26, 2023
Details:
Arakoda (tafenoquine) oral tablet is being developing the tafenoquine regimen of ARAKODA® for a potential indication in treating hospitalized babesiosis patients. The meeting will take place on January 15, 2024.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and older.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and older.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Arakoda (tafenoquine) oral tablet is being investigated in Phase IIB Study for COVID-19 patients with mild-moderate symptoms and low risk of disease and is approved by FDA for the treatment of prophylaxis of malaria in patients aged 18 years of age and older.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
ARAKODA (tafenoquine) an oral tablet, is an anti-malarial indicated in the U.S. for the prophylaxis of malaria in individuals aged 18 years and older.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
The net proceeds will be used to fund the development of new indications for comapny's products with a focus on executing a COVID-19 clinical trial involving Arakoda (tafenoquine) which is active against SARS-CoV-2 at clinically relevant concentrations.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: WallachBeth Capital
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 14, 2023
Details:
Arakoda (tafenoquine) inhibits SARS-CoV-2 replication in monkey kidney and human epithelial cells, and pharmacokinetic simulations suggest lung levels at the FDA-approved dose for malaria prevention may exceed the EC90 of the drug.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Clinical trial data suggesting that ARAKODA® (tafenoquine) exhibits a positive therapeutic signal in mild-moderate COVID-19 disease have been published in New Microbes and New Infections, a peer-reviewed, open-access journal.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
In vitro testing and modeling and simulation with Certara’s Simcyp™ Simulator demonstrate that tafenoquine shows antiviral activity at concentrations that are pharmacologically relevant and may be achievable in lung tissue.
Lead Product(s): Tafenoquine
Therapeutic Area: Infections and Infectious Diseases Product Name: Arakoda
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
